论文部分内容阅读
目的:探讨顺铂联合国产多西他赛治疗晚期非小细胞肺癌的临床疗效及其毒性反应。方法:选择2010年7月~2013年7月我院收治的非小细胞肺癌患者共38例,采用顺铂联合国产多西他赛化疗方案,观察患者疗程结束后的疗效以及毒性反应。结果:CR病例1例(2.63%)、PR病例12例(31.58%)、NC病例21例(55.26%)、PD病例4例(10.53%),治疗有效率为34.21%、临床获益率为89.47%;主要毒副反应主要为骨髓抑制、消化道反应以及脱发。结论:顺铂联合国产多西他赛能够获得良好的近期疗效以及临床获益率,且化疗毒副反应能够耐受,值得在临床工作中进一步深入研究。
Objective: To investigate the clinical efficacy and toxicity of cisplatin combined with docetaxel in the treatment of advanced non-small cell lung cancer. Methods: Thirty-eight patients with non-small cell lung cancer who were treated in our hospital from July 2010 to July 2013 were selected and treated with cisplatin combined with docetaxel chemotherapy regimen to observe the curative effect and toxicity of the patients after the end of treatment. Results: One case (2.63%) of CR patients, 12 cases (31.58%) of PR cases, 21 cases (55.26%) of NC cases, 4 cases (10.53%) of PD cases, the effective rate was 34.21% 89.47%. The main toxicities were myelosuppression, gastrointestinal reaction and alopecia. CONCLUSION: Cisplatin combined with docetaxel can achieve good short-term efficacy and clinical benefit rate, and chemotherapy toxicity can be tolerated. It is worth further study in clinical work.